Fiasp PumpCart (insulin aspart)
Submitted by Anonymous (not verified) on 18 December 2025 - 11:11
Fiasp PumpCart (insulin aspart)
Name Review Group form - questions and answers
Submitted by Anonymous (not verified) on 18 December 2025 - 11:10
Name Review Group form - questions and answers
NovoRapid PumpCart (insulin aspart)
Submitted by Anonymous (not verified) on 18 December 2025 - 11:02
NovoRapid PumpCart (insulin aspart)
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 18 December 2025 - 10:46
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 11, Status: Authorised
Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations - Scientific guideline
Submitted by Anonymous (not verified) on 18 December 2025 - 10:10
Allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations - Scientific guideline
Human medicines European public assessment report (EPAR): Invokana, canagliflozin, Date of authorisation: 15/11/2013, Revision: 27, Status: Authorised
Submitted by Anonymous (not verified) on 18 December 2025 - 9:46
Human medicines European public assessment report (EPAR): Invokana, canagliflozin, Date of authorisation: 15/11/2013, Revision: 27, Status: Authorised
EMA/PE/0000232894
Submitted by Anonymous (not verified) on 18 December 2025 - 9:26
EMA/PE/0000232894
Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 November 2025
Submitted by Anonymous (not verified) on 18 December 2025 - 9:19
Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 November 2025
EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 November 2025, 13:30 (CET) to 14 November 2025, 17:30 (CET)
Submitted by Anonymous (not verified) on 18 December 2025 - 9:16
EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 November 2025, 13:30 (CET) to 14 November 2025, 17:30 (CET)
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Date of authorisation: 27/06/2025, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 17 December 2025 - 15:46
Human medicines European public assessment report (EPAR): Ziihera, zanidatamab, Date of authorisation: 27/06/2025, Revision: 1, Status: Authorised